Related Experiment Video
Updated: Aug 27, 2026

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
Published on: June 30, 2017
Identification of anti-NSCLC bioactive compounds from Euphorbia helioscopia L. through integrated pharmacological
Xiaomei Yu1, Caihong Bai2, Tao Wang1
1State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China; School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, China.
Abstract:
Euphorbia helioscopia L. (commonly known as Zeqi) has been reported to possess anti-tumor potential, however, its bioactive constituents and underlying molecular mechanisms against non-small cell lung cancer (NSCLC) remain to be elucidated. This study aimed to systematically identify anti-NSCLC components and explore their associated mechanisms through integrated pharmacological classification and metabolomics analysis. Zeqi samples exhibiting distinct in vitro antiproliferative activities were first classified into relatively higher-activity (RHA) and relatively lower-activity (RLA) group, and then subjected to metabolomics profiling using ultra performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS) and subsequent univariate and multivariate statistical analysis. Four compounds (fraxetin, 2''-O-galloylhyperoside, isofraxidin and myricitrin 3-O-galactoside) were identified as candidate bioactive constituents associated with the antiproliferative activity of Zeqi. Among these, fraxetin exhibited the most potent inhibitory effect against NSCLC cells. Flow cytometric analysis revealed a dose-dependent increase in apoptotic rates. Transcriptomic analysis indicated that fraxetin regulates the expression of apoptosis-related genes and activates apoptotic pathways. Further reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analyses confirmed that fraxetin-induced apoptosis in NSCLC cells might be associated with its ability to upregulate Noxa and downregulate Mcl-1 at both transcriptional and translational levels. In conclusion, the successful application of integrated pharmacological classification and metabolomics analysis not only enabled the identification of anti-NSCLC active components in Zeqi but also provides a robust methodological framework for efficient discovery of bioactive lead compounds from complex traditional Chinese medicine (TCM) systems.
More Related Videos
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
08:44Elucidation of the Material Basis of Yiqi Qingjie Formula Against IgA Nephropathy Using UHPLC-Q-Orbitrap HRMS Integrated with Network Pharmacology
Published on: May 19, 2026